Transforming growth factor-b1 (TGF-b1) is one of very few cytokines produced in a latent form, requiring activation to exert any of its vastly diverse effects on development, immunity, and cancer. Regulatory T cells (T regs ) suppress immune cells within close proximity by activating latent TGF-b1 presented by GARP (glycoprotein A repetitions predominant) to integrin aVb8 on their surface. We solved the crystal structure of GARP:latent TGF-b1 bound to an antibody that stabilizes the complex and blocks release of active TGF-b1. This finding reveals how GARP exploits an unusual medley of interactions, including fold complementation by the amino terminus of TGF-b1, to chaperone and orient the cytokine for binding and activation by aVb8. Thus, this work further elucidates the mechanism of antibody-mediated blockade of TGF-b1 activation and immunosuppression by T regs .
C ytokines of the transforming growth factor-b (TGF-b) family exert widespread and diverse effects on metazoan cells (1) . Owing to their potency and pleiotropy, family members such as the closely related TGF-b1, -b2, and -b3 isoforms are produced as latent, inactive cytokines, which require a tightly regulated step of extracellular activation to acquire the ability to bind their cognate heterotetrameric receptor (2, 3) . The mechanisms of TGF-b activation appear to be isoform-and cell type-specific, but none have been fully elucidated on a structural basis.
TGF-b1 is the predominant isoform expressed by immune cells, including the immunosuppressive FOXP3 + CD4 + regulatory T cells known as T regs (4) . Immunosuppression by T regs prevents autoimmunity but is detrimental in cancer or chronic infections (5) . T regs suppress other immune cells within close proximity by activating latent TGF-b1 on their surface (6) . This results from the following multistep process. Newly synthesized pro-TGF-b1 homodimers form disulfide bonds with GARP (also known as LRRC32), a transmembrane protein retained at the surface of T regs and a few other cell types (7) (8) (9) (10) (11) . Pro-TGF-b1 is then cleaved by furin to produce latent TGF-b1, in which the C-terminal dimer, or mature TGF-b1 (mTGF-b1), remains noncovalently associated to the N-terminal dimer known as LAP (latency associated peptide). Latent TGF-b1 is inactive because the two LAP monomers, by means of their arm and "straightjacket" domains, form a ring around mTGF-b1, masking the interaction sites with the TbRI and TbRII receptor chains (12) . TGF-b1 activation entails the release of mTGF-b1 from LAP. Tensile force exerted by the cytoskeleton and transmitted by integrin aVb6 to LAP is hypothesized to unfasten and elongate the straightjacket, leading to the release and activation of mTGF-b1 (13) . However, this mechanism of activation is restricted to cells expressing aVb6. T regs lack aVb6. Instead, latent TGF-b1 presented by GARP on the surface of T regs is activated by integrin aVb8. This was shown using antibodies against either the GARP:(latent)TGF-b1 complex or the b8 integrin subunit, which block TGF-b1 activation and immunosuppression by T regs (6, 14) . Despite these advances in our understanding of TGF-b1 activation, the mechanism by which GARP structurally contributes to activation via integrin aVb8 has eluded the field. Thus, we sought to determine the crystal structure of GARP bound to latent TGF-b1 by using a specific helper antibody to stabilize the complex.
We first coexpressed the extracellular domain of human GARP (GARP ECD ) and latent TGF-b1 and purified a soluble form of the GARP ECD :TGF-b1 binary complex for x-ray crystallography. As this complex proved recalcitrant to crystallization, we reasoned that a ternary assembly with a Fab fragment might be more amenable to crystallization. We chose to use the Fab derived from the monoclonal antibody MHG-8 because it binds GARP:TGF-b1 complexes but not free GARP and blocks TGF-b1 activation by T regs (6) . Resolving such a complex would also provide key insights into therapeutically relevant epitopes.
Preparative reconstitution of GARP ECD :TGFb1:MHG-8 Fab complexes yielded crystals that enabled determination of a structure to 3.1-Å resolution ( fig. S1 and table S1 ). The structure features a tripartite assembly obeying a 1:1:1 stoichiometry, comprising one molecule of GARP ECD , one complex of latent TGF-b1 (i.e., one LAP A / LAP B and one mTGF-b1 A /mTGF-b1 B dimer), and one copy of MHG-8 Fab (Fig. 1A and table S2 ). The structure provided a snapshot of how latent TGF-b1 is sequestered by GARP via an intricate combination of covalent and noncovalent interactions. Tethering of latent TGF-b1 by GARP occurred on the opposite side from the RGD integrin-binding motifs in LAP (9, 13) , in an orientation compatible with integrin aVb8 binding (Fig. 1A) .
GARP ECD adopted a solenoid horseshoe structure with a nearly perfect circular curvature and featured 20 leucine-rich repeats (LRRs, R1 to R20) capped by N-and C-terminal motifs (Fig. 1B) . Each repeat, comprising a consensus sequence of 21 to 29 residues, manifested a hydrophobic core running through the horseshoe solenoid (Fig. 1C) . The concave side of the horseshoe was lined by an extended b sheet of parallel b strands contributed by each of the 20 repeats and the two capping motifs (Fig. 1, B to D) . This side also displayed N-linked glycosylation at four of the five predicted sites (Fig. 1B) . The convex side displayed an irregular mix of secondary structures connected by loops of various lengths (Fig. 1B  and fig. S2 ). The GARP scaffold was further stabilized by two intrachain disulfide bonds: one (Cys ) anchoring the ends of an otherwise disordered loop protruding from the convex side of R15 (Fig. 1B) . This structure of GARP may serve as a structural prototype for LRRC33, the only other LRR protein known to bind and present latent TGFb1 on cell surfaces and that shares high levels of sequence identity with GARP ( fig. S2) (15, 16) .
The most mechanistically relevant insights from our structure center on the GARP ECD :TGF-b1 interface ( Fig. 2 and figs. S2 to S4). Half (28 of 56) of the GARP residues interacting with latent TGF-b1 were conserved in LRRC33 ( fig. S2 ). Thus, LRRC33 may interact with latent TGF-b1 in a manner similar to GARP. Most residues (22 of 33) of latent TGF-b1 involved in the interaction with GARP were conserved in TGF-b2 and -b3, which also associate with GARP (figs. S4 and S5, A and B) (17) . Thus, GARP is poised to actively regulate the bioavailability of all three TGF-b isoforms.
The GARP ECD :TGF-b1 complex unmasked rarely seen combinations of structural features, not only due to the diversity and extent of its interaction landscape but also because it involved a twofold-symmetric growth factor (latent TGF-b1), bound by a molecular partner (GARP) , that lacks any element of symmetry. Our structure revealed that latent TGF-b1 uses both copies of LAP and only one of the two mTGF-b1 modules to saddle the side of the GARP horseshoe. This results in three main interfaces, namely GARP:mTGF-b1 B , GARP:LAP A , and GARP:LAP B ( Fig. 2A) . The binding footprint of latent TGF-b1 to GARP comprised the ascending lateral and convex surfaces roughly halfway into the horseshoe (R4 to R11) and buried a total of~1750 Å 2 of molecular surface area. Latent TGF-b1 interacted with a predominantly hydrophobic cushion in GARP via van der Waals contacts mediated by the Nterminal loop of LAP A and LAP B , by the loop comprising residues 323 to 337 in mTGF-b1 B , and by helix a3 in mTGF-b1 B ( Fig. 2A, i) .
Two structural features were particularly no- Fig. 2A , ii and iii) (9) . Covalent linkage between distinct proteins is an unusual mode of interaction when redox regulation is not at play. The LAP A -GARP disulfide was nested in a hydrophobic pocket capped by Trp 297 of GARP ( Fig. 2A, ii) . Second, the N-terminal loop of LAP A inserted into a hydrophobic pocket formed by strands b12 in R6 and b14 in R7 of GARP ( Fig. 2A, ii) . This unanticipated structural feature led to complementation of the GARP horseshoe fold by a b-strand addition contributed by LAP A (strand b1A), supporting a role of GARP as a molecular chaperone for latent TGF-b1 biogenesis. GARP sealed this unusual interaction by inserting a b hairpin formed by residues 290 to 299. Notably, this hairpin was the only ordered part within a long segment (residues 280 to 317) that originates at R10 and was predicted to be intrinsically disordered (Fig. 1B and fig. S2 ). A binding mode of this nature was proposed to partially compensate for the high entropic cost associated with the binding of intrinsically disordered segments to partner molecules. However, structural snapshots of this phenomenon have only rarely been experimentally observed (18) .
Our structure unveiled the structural plasticity of latent TGF-b1 and conformational changes that underlie its sequestration by GARP. The structure of latent TGF-b1 bound to GARP was globally similar to that of unbound porcine latent TGF-b1 (12) , with structural disorder in the bowtie region that can associate with aVb6 integrin (13) . However, it displayed three drastic local conformational changes compared with all TGF-b1 structures known to date. First, helix a3 in mTGF-b1 B became a 3 10 helix element (h1) and was rotated upward by 45° (Fig. 2B) . Second, the preceding loop with residues 323 to 337 was substantially restructured toward the GARP concavity (Fig. 2B) 
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switching resolved otherwise severe steric clashes and introduced Tyr 336 of mTGF-b1 B into a new structural context stabilized by a stacking interaction with Tyr 137 of GARP and by hydrogen bonding between its main-chain atoms and Ser 160 of GARP ( Fig. 2A) . Third, helix a1 in LAP B , which mediates interactions between LAP B and GARP, underwent marked unwinding while remaining physically tethered to GARP via the LAP B -GARP disulfide (Fig. 2, A and C) . Unwinding of helix a1 was also seen in LAP A . Collectively, such extensive structural plasticity in latent TGF-b1 in a region far from the integrin binding site may explain why it can associate with two structurally very distinct classes of proteins. Namely, GARP or LRRC33 on one hand and LTBPs (latent TGF-b binding proteins) on the other (15) .
The MHG-8 Fab used to generate the crystals blocked TGF-b1 activation by human T regs as efficiently as the full MHG-8 antibody (Fig. 3A) . Thus, our crystal structure also revealed how an antibody can block TGF-b1 activation from GARP:TGF-b1 complexes and antagonize T reg suppression (6). MHG-8 bound a mixed conformational epitope, concomitantly contacting residues from GARP and latent TGF-b1 (Figs. 1A and 3, B to D) . Specifically, CDR1 and CDR3 of the MHG-8 light chain and CDR3 of the heavy chain contacted the convex side of GARP, whereas the heavy chain also contacted the C-terminal arm domain of LAP B and the 3 10 helix h1 of mTGF-b1 B via its CDR2, CDR3, and framework regions (Fig. 3, C and D, and figs. S6 to S8). We confirmed involve- Fig. 3B) . A majority (9 of 17) of LAP or mTGF-b1 residues in contact with MHG-8 were not conserved in the corresponding positions of TGF-b2 and -b3. This explains why MHG-8 does not bind GARP:TGF-b3 complexes and only binds GARP:TGF-b2 with very low affinity (figs. S4 and S5C).
The antagonistic activity of MHG-8 on T regs may result from its ability to impair the release of mTGF-b1 induced by combined pulling by integrin aVb8 on one side and resistance or synergistic pulling by GARP on the other side of LAP (Figs. 3C and 4) . By simultaneously contacting amino acids in the arm of LAP B and in GARP, MHG-8 may reinforce the fastening of the straightjacket, preventing the elongation required to release mTGF-b1 (Figs. 3C and 4) . Alternatively, by cross-linking amino acids in GARP with the 3 10 helix h1 of mTGF-b1 B , MHG-8 may prevent the release of mTGF-b1 and immobilize its 3 10 helix h1 in a position that is incompatible with binding to the TbRI chain of its receptor, even if the straightjacket is elongated and relaxed. In either scenario, MHG-8 sterically prevents mTGF-b1 release by engaging both GARP and latent TGF-b1 while still allowing binding of aVb8, as demonstrated previously (14) .
Thus, we elucidate the role of GARP in TGFb1 biogenesis and activation, as well as the mechanistic principles underlying antibodymediated blockade of TGF-b1 activation and immunosuppression by human T regs . Visualization of this large molecular assembly illustrates the feasibility of blocking TGF-b1 activity emanating from a precisely defined and restricted cellular source, such as the surface of T regs . This work also suggests how other TGF-b1-presenting proteins, such as LTBPs deposited in the extracellular matrix (2, 19) , may operate as alternative Structural analyses of a pro-TGF-b1 monomer bound by the integrin aVb6 head show how cytoskeletal forces elicit reshaping of latent TGF-b1 to release mTGF-b1 from LAP (13) . Maximal harnessing of such forces depends on the direction of the force vector (20) . Thus, GARP may provide strong anchoring to the cell surface, with its juxtamembrane region providing the necessary flexibility that allows for the optimal alignment of pulling-force vectors. Our crystal structure also suggests how an antibody can block TGF-b1 activation from GARP:TGF-b1 complexes on T regs by cross-linking GARP to one LAP and one mTGF-b1 monomer, which sterically prevents mTGF-b1 release while still allowing integrin aVb8 binding. sources of active TGF-b1 and may also be specifically targeted by antibody-or small-moleculebased reagents. Such structural and mechanistic insights may facilitate the design of particularly specific approaches to treat various diseases associated with altered TGF-b1 activity and/or dysfunctional T reg responses, most notably for cancer immunotherapy.
